Home » Stocks » CANF

Can-Fite BioPharma Ltd. (CANF)

Stock Price: $1.90 USD 0.00 (0.00%)
Updated Jan 19, 2021 10:01 AM EST - Market open
Market Cap 29.73M
Revenue (ttm) 580,571
Net Income (ttm) -2.74M
Shares Out 2.69M
EPS (ttm) -1.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $1.90
Previous Close $1.90
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.92
Day's Range 1.88 - 1.92
Day's Volume 34,101
52-Week Range 1.13 - 2.76

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers

Newsfile Corp - 2 weeks ago

Petach Tikva, Israel--(Newsfile Corp. - January 4, 2021) - Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs th...

Business Wire - 1 month ago

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address ...

Business Wire - 1 month ago

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Reports on Progress with its Namodenoson NASH Program

Seeking Alpha - 1 month ago

Can-Fite BioPharma Ltd. (CANF) CEO Pnina Fishman on Q3 2020 Results - Earnings Call Transcript

Business Wire - 1 month ago

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical Update

Business Wire - 1 month ago

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite's Namodenoson Abstract Selected as ‘Best of The Liver Meeting ‘ in the NASH Category of the American Association of Liver Diseases (AASLD)

Business Wire - 1 month ago

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Conduct Investor Call to Review Q3 Results and Provide Business Update on Monday, November 30, 2020 at 9:15 a.m. ET

Business Wire - 2 months ago

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of AASLD Conference

InvestorPlace - 2 months ago

With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 ...

Other stocks mentioned: FPRX, GTBP, IFRX, TNXP, VTVT, VXRT
Business Wire - 2 months ago

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020

Business Wire - 3 months ago

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020

Business Wire - 3 months ago

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address ...

Business Wire - 3 months ago

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Selected to Deliver Late-Breaking Presentation on Namodenoson’s Treatment of NASH at American Association for the Study of Liver Diseases

Business Wire - 3 months ago

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Participate in Two BioPharma Partnering Conferences

Business Wire - 4 months ago

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020

Business Wire - 4 months ago

PETACH TIKVA, Israel--(BUSINESS WIRE)--FDA Clears Can-Fite to Commence Phase II COVID-19 Study

Seeking Alpha - 4 months ago

Can-Fite BioPharma Ltd. (CANF) CEO Pnina Fishman on Q2 2020 Results - Earnings Call Transcript

Business Wire - 4 months ago

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address ...

Business Wire - 4 months ago

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH

Business Wire - 4 months ago

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Conduct Investor Call to Review Q2 Results and Provide Business Update on Thursday, August 27, 2020 at 4:15 p.m. ET

Business Wire - 5 months ago

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study

Business Wire - 5 months ago

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds

Business Wire - 6 months ago

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly

Seeking Alpha - 7 months ago

Can-Fite BioPharma Ltd. (CANF) CEO Pnina Fishman on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 27th

Other stocks mentioned: ATXI, GFI, MN
Benzinga - 9 months ago

As the COVID-19 pandemic continues to ravage the globe, having claimed over 115,000 lives, health care companies have are pursuing diagnostics tests, potential vaccines and therapies.

Other stocks mentioned: ATHX, BCRX, BIOC
Benzinga - 9 months ago

Can-Fite BioPharma (NYSE: CANF) shares were trading higher on Tuesday, after the company announced it achieved its main study endpoint in phase 2 NASH study with Namodenoson were dose-dependent.

Benzinga - 10 months ago

The following are the latest biotech announcements from late Thursday and Friday morning on the development of products targeting the coronavirus.

Other stocks mentioned: AYTU, ENTA, LJPC, LLY, OPK, RHHBY
Zacks Investment Research - 10 months ago

Can-Fite (CANF) announces plans to explore piclidenoson for the treatment of coronavirus.

GlobeNewsWire - 11 months ago

PETACH TIKVA, Israel, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule ...

Benzinga - 1 year ago

Can-Fite BioPharma Ltd CANF 3.77% , an Israeli biotechnology company with a pipeline of proprietary compounds in Phase 2 and 3 clinical development stage that address autoimmune-inflammator...

Benzinga - 1 year ago

Israeli biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) said Monday that its drug candidate Piclidenoson for the treatment of osteoarthritis in mammals has been granted Patent No.

Benzinga - 1 year ago

Biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) announced Tuesday it has partnered with the medical cannabis company Univo Pharmaceuticals to work on developing cannabinoid-based ph...

Market Watch - 1 year ago

Shares of Can-Fite Biopharma Ltd. CANF, -2.05% soared 18% in active premarket trading Tuesday, after the Israel-based drug development company announced a collaboration agreement with Israeli ...

Benzinga - 1 year ago

Can-Fite BioPharma (NYSE: CANF) announced a new deal with Kyongbo Pharm to distribute the drug Piclidenoson for Psoriasis in South Korea, receiving $4 million payment upfront.

Benzinga - 1 year ago

Can-Fite BioPharma (NYSE: CANF) 6-K shows the company filed an appeal with the Supreme Court of Israel of a decision related to the convening of a special shareholder meeting to replace direct...

Zacks Investment Research - 1 year ago

Can-Fite (CANF) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 1 year ago

In Q1/2019, Can-Fite reported that Namodenoson didn’t achieve the primary endpoint in the Phase 2 liver cancer study, but achieved superiority in median overall survival in a subgroup.

Benzinga - 1 year ago

Shares of the biotech Can-Fite Biopharma Ltd were skyrocketing Monday after an abstract describing data from the company's liver cancer study of the drug namodenoson was selected by the Intern...

About CANF

Can-Fite BioPharma, a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis;... [Read more...]

Industry
Biotechnology
Founded
1994
CEO
Pnina Fishman
Employees
8
Stock Exchange
NYSEAMERICAN
Ticker Symbol
CANF
Full Company Profile

Financial Performance

In 2019, CANF's revenue was 2.03 million, a decrease of -46.81% compared to the previous year's 3.82 million. Losses were -9.59 million, 45.9% more than in 2018.

Financial numbers in millions ILS.
Financial Statements

Analyst Forecasts

According to one analyst, the rating for CANF stock is "Buy" and the 12-month stock price forecast is 5.00.

Price Target
$5.00
Analyst Consensus: Buy